Pharmaceutical

Antengene and Hansoh partner to commercialise XPOVIO in China

Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.

Aug 12, 2023 - 20:00
Antengene and Hansoh partner to commercialise XPOVIO in China
Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.
Read the original article

Tags:

Previous Article

Absci and Caltech receive grant to develop HIV therapeutic vaccine

Next Article

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The case against age limits for politicians

Opinion: The case against age limits for politicians

Oct 4, 2023

Lupin sees highest patent filings and grants during Sep...

Dec 10, 2023

BIO-Europe 2023: Barriers remain in the AI pharma revolution

BIO-Europe 2023: Barriers remain in the AI pharma revol...

Nov 12, 2023